(Q35048263)

6 August 2017

1 reference

title

Emerging therapies of hepatitis B and C. (English)

1 reference

6 August 2017

Robert Y M Chen

1

1 reference

6 August 2017

Paul V Desmond

series ordinal

2

1 reference

6 August 2017

Stephen A Locarnini

series ordinal

3

1 reference

6 August 2017

language of work or name

1 reference

1 December 2002

1 reference

Journal of Gastroenterology and Hepatology

6 August 2017

1 reference

6 August 2017

17 Suppl

1 reference

6 August 2017

S471-81

1 reference

Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis

6 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Prevalence of Hepatitis C Virus Antibody Among Korean Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Transmission of hepatitis C virus in Taiwan: prevalence and risk factors based on a nationwide survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Ribavirin treatment for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and -pyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Functional inactivation of genes by dominant negative mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Gene inhibition using antisense oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Inhibition of hepatitis C virus replication by antisense oligonucleotide in culture cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Relationship between the presence of circulating anti-GOR and hepatitis C viremia/genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Prospects for active immunotherapies for hepatitis B virus chronic carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Therapy for human immunodeficiency virus infection -- what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Lamivudine as initial treatment for chronic hepatitis B in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Lamivudine resistance inimmunocompetent chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

Presence of ATP-dependent copper transport in the hepatocyte canalicular membrane of the Long-Evans cinnamon rat, an animal model of Wilson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S4.13.X

10.1046/J.1440-1746.17.S4.13.X

21 January 2018

Identifiers

DOI

1 reference

release_7lu7lseij5fjxf7gljilz54mpy

6 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7lu7lseij5fjxf7gljilz54mpy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference